NADMED

About:

Nadmed brings to market a new type of NAD metabolite measurement technology.

Twitter/X: NADMED_Ltd/status/1600723549987086336

Top Investors: Business Finland, Voima Ventures, Nordic Science Investments, University of Helsinki

Description:

The NADMED test was developed by one of the world's foremost experts on NAD metabolism in humans. NADMED's metabolite extraction system is the only method for measuring all four NADs and glutathione.

Total Funding Amount:

3.5M EUR

Headquarters Location:

Helsinki, Southern Finland, Finland

Founded Date:

2022-01-01

Contact Email:

info(AT)nadmed.com

Founders:

Number of Employees:

11-50

Last Funding Date:

2024-08-22

IPO Status:

Private

Industries: